Introduction
============

Mammalian aquaporins (AQPs) are a family of 13 integral membrane channel proteins termed AQP0--AQP12, facilitating the transport of water, small solutes, and gasses across biological membranes ([@B2]; [@B154]). Comparatively, transport properties among the different AQPs are quite heterogeneous, reason why their exhaustive classification represents a difficult task. Mammalian AQPs are roughly subdivided in three subfamilies: (1) the classical AQPs, permeable to water (AQP0, AQP1, AQP2, AQP4, AQP5, AQP6, and AQP8) ([@B2]; [@B154]); (2) the aquaglyceroporins, permeable to small solutes including urea and glycerol, in addition to water (AQP3, AQP7, AQP9, and AQP10) ([@B2]; [@B154]; [@B135]); and (3) unorthodox AQPs with suggested permeability to water (AQP11, AQP12) and glycerol (AQP11) ([@B62]). Some AQPs are also permeable to H~2~O~2~ (AQP1, AQP3, AQP5, AQP8, and AQP9) and/or ammonia (AQP1, AQP3, AQP4, AQP6, AQP7, AQP8, and AQP9) ([@B65]; [@B47]), and for these biophysical properties they are also called peroxiporins ([@B3]) and ammoniaporins (or aquaammoniaporins) ([@B57]; [@B138]; [@B3]), respectively. Among aquaglyceroporins, AQP9 exhibit broad selectivity toward several neutral solutes including urea, carbamides, nucleosides, monocarboxylates, pyrimidines, purines and metalloid arsenic in addition to glycerol and other polyols ([@B153]; [@B88]).

AQPs also allow movement of gasses such as CO~2~ (AQP1, AQP4, and AQP5), NO (AQP1, AQP4) or O~2~ (AQP1, AQP4) ([@B54]; [@B138]; [@B161]; [@B13]).

The expression of aquaglyceroporins has been documented in many body locations including adipose tissue, liver, and pancreas where they are reported to play important metabolic functions ([@B135]). This review aims to present the current knowledge on the role of aquaglyceroporins in adipose tissue, liver and endocrine pancreas, and their possible use as drug targets for metabolic diseases.

Role of Aquaglyceroporins in Adipose Tissue
===========================================

Physiological Conditions
------------------------

Considering the role of aquaglyceroporins in adipose tissue has been subjected to extensive reviews (see [@B42]; [@B98]; [@B95]; [@B74]; [@B32]), a brief summary is given here after on this topic. The first adipose aquaglyceroporin that has been identified in human, mouse and rat is AQP7 ([@B61], [@B63]; [@B70]; [@B71]). Differentiation of mice 3T3-L1 cells into adipocytes leads to an increased expression in *Aqp7* mRNA ([@B7]; [@B112]; [@B30]) and AQP7 protein ([@B31]). Differentiation of human preadipocytes into adipocytes also leads to an increased expression in both *Aqp7* mRNA and protein ([@B111]). While studies reported AQP7 expression exclusively in endothelial cells surrounding adipocytes ([@B140]; [@B80]), other studies reported AQP7 expression in both endothelial cells and adipocytes ([@B75]; [@B112]). Subsequently, other aquaglyceroporins have been detected in human adipocytes: AQP3 ([@B130]), AQP9 ([@B130]), and AQP10 ([@B75]). However, the presence of AQP3, AQP9, and AQP10 in human adipose tissue was not supported by all studies as [@B111] only detected AQP7 and [@B85] failed to detect AQP9. In mouse 3T3L-1 cells differentiated into adipocytes, the presence of AQP3, AQP7, and AQP9 has also been found ([@B30], [@B31]). In mouse 3T3-L1 cells differentiated into adipocytes, no modification in *Aqp3* and *Aqp9* mRNA levels were detected ([@B30]), while both AQP3 and AQP9 protein levels were increased ([@B31]). On the other hand, some studies did not show the presence of AQP3 and AQP9 in mouse adipose tissue ([@B69]; [@B97]) or 3T3-L1 cells differentiated into adipocytes ([@B69]). In addition, AQP11, an unorthodox AQP, has recently been shown to be permeable to glycerol and present in human and mouse adipocytes ([@B94]; [@B30]). While AQP10 is expressed in human, it is a nonfunctional pseudogene in mice ([@B114]). In human adipocytes, AQP10, localized in the cytoplasm and the lipid droplets, undergoes translocation to the plasma membrane upon isoproterenol stimulation (inducing lipolysis), suggesting AQP10 could be involved in glycerol exit during lipolysis ([@B75]). In rat adipocytes, AQP3 expression has been detected while, to our knowledge, expression of AQP9 and AQP10 expression have not yet been reported ([@B107]).

In adipocytes, aquaglyceroporins display different subcellular localizations and are subjected to trafficking in response to hormonal stimulation, including insulin and cAMP-inducing hormones ([@B130], [@B131]; [@B112]; [@B50]). Aquaglyceroporins present in adipose tissue are transcriptionally regulated by hormones (such as insulin, catecholamines, and steroids) and inflammatory mediators (such as TNFα, and lipopolyssacharides) ([@B70]; [@B71]; [@B41]; [@B130]; [@B30]). In addition, human *Aqp7* and mouse *Aqp7* transcriptional activity is upregulated by peroxisome proliferator-activated receptor gamma (PPARγ) ([@B70]; [@B84]). Finally, a very recent study showed that *Aqp7* transcription is also controlled by the transcription factor Küppel-like factor 15 (KLF-15), known be involved in insulin-triggered lipogenesis ([@B72]).

From a metabolic point of view, adipose tissue is a major source of triacylglycerols (TAG) storage during feeding, as well as a major source of plasma glycerol during fasting ([@B128]; [@B6]). Indeed, both TAG synthesis and storage are promoted during feeding, while TAG degradation occurring during lipolysis upon TAG lipase activation is promoted during fasting.

Experiments using differentiated adipocytes ([@B69]) and *Aqp7* knockout mice ([@B97]; [@B51]; [@B55]) evidenced the role of AQP7 in glycerol release from adipocytes. AQP3 and AQP9 were also proposed to play a role in glycerol release during lipolysis or in glycerol intake during lipogenesis, respectively ([@B130]). Following isolation from omental adipose tissue, human stromovascular fraction cells expressed approximately a 12-fold higher *AQP3* mRNA level as compared to adipocytes, suggesting that AQP3 is predominantly expressed by other cell types (e.g., preadipocytes, macrophages, fibroblasts, erythrocytes, neutrophils, and leukocytes) than in adipocytes from adipose tissue ([@B130]). The involvement of AQP9 in adipocyte glycerol uptake has been suggested by several data. Firstly, the expression of AQP9, localized at the plasma membrane from mouse 3T3-L1 cells differentiated into adipocytes, and increased in response to insulin ([@B130]). Secondly, in human omental adipocytes, the expression of AQP9, but also of AQP3 and AQP7, is increased by insulin, while the expression of AQP9, and also of AQP7, is decreased by leptin though the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTor) pathway ([@B130]). However, during lipogenesis, glycerol uptake is likely limited due to the low activity of the adipose glycerol kinase (GK).

In mouse 3T3-L1 cells differentiated into adipocytes, hormones activating the cAMP pathway induced the translocation of AQP3 and AQP7, localized within intracellular vesicles, to the plasma membrane, while the plasma membrane localization of AQP9 was unchanged ([@B130]). Insulin induced an increased intracellular localization of AQP3 and AQP7 and an increased plasma membrane localization of AQP9 in 3T3-L1 cells differentiated into adipocytes ([@B130]) (as stated above). Using selective AQPs inhibitors, it was possible to estimate biophysically the relative contributions of AQP3, AQP7, and AQP9 to the glycerol permeability (measured as *Ki*, an index reflecting the membrane glycerol permeability) of plasma membrane vesicles prepared from mouse 3T3-L1 cells differentiated into adipocytes were estimated to 68, 3, and 12%, respectively ([@B31]). The relative contributions of AQP3, AQP7, and AQP9 to the membrane glycerol permeability were estimated using the following formulas; \[(*Ki* in the absence of inhibitor -- *Ki* in the presence of CuSO~4~)/(*Ki* in the absence of inhibitor)\]; \[(*Ki* in the presence of HgCl~2~ -- *Ki* in the presence of phloretin)/(*Ki* in the absence of inhibitor)\]; \[*Ki* measured in the presence of CuSO~4~ -- *Ki* in the presence of HgCl~2~)/(*Ki* in the absence of inhibitor)\]. In 3T3-L1 cells differentiated into adipocytes, the low (3%) relative contribution of AQP7 to glycerol permeability ([@B31]) might be underestimated due to possible incomplete effects of the inhibitors, while the important (45%) reduction in glycerol release in the cell media following AQP7 knockdown using RNAi might be overestimated due to possible off target effects of RNAi ([@B55]). Based on these data, an updated model of the role of aquaglyceroporins in the regulation of lipogenesis and lipolysis was recently proposed: whereby mainly AQP3 and AQP7 would play a role in glycerol release during lipolysis, while mainly AQP9 would play a role in limited glycerol uptake that may occur during lipogenesis ([@B31]). Understanding the role of each aquaglyceroporin in adipose tissue remains to be fully elucidated using mice made deficient, in a tissue-specific manner, for one or multiple aquaglyceroporin gene(s).

**Figure [1](#F1){ref-type="fig"}** summarizes the roles played by aquaglyceroporins in adipose tissue under fasted and fed states in mouse.

![Glycerol metabolism: working model of the interplay between the liver and adipose tissue in fed and starved states in mouse. During fasted state, glucagon secretion is induced, TAG are hydrolyzed to glycerol and free fatty acids in adipocytes, and both AQP7 and AQP3 traffic to the plasma membrane and participate with AQP9 to glycerol efflux. AQP9 allows plasma glycerol entry in hepatocytes. Glycerol is then converted to glycerol-3-phosphate by glycerol kinase, and thereby participates to gluconeogenesis. During fed state inducing insulin secretion, glucose metabolites, glycerol-3-phosphate (obtained from glycerol by glycerol kinase enzymatic activity) and free fatty acids are used to produce TAG in both liver and adipose tissue. In response to insulin in adipocytes, AQP3 and AQP7 traffic from the plasma membrane to intracellular compartments. Glycerol most likely mainly enters adipocytes via AQP9. During lipogenesis, adipose glycerol uptake is likely low due to the weak activity of the glycerol kinase. In hepatocytes, glycerol likely enters via AQP7 and AQP9. ATGL, adipose triglyceride lipase; GK, glycerol kinase; Glut2, glucose transporter 2; Glut4, glucose transporter 4; G3P, glycerol-3-phosphate; FFA, free fatty acids; HSL, hormone sensitive lipase; TAG, triacylglycerols; broken arrows: trafficking.](fphys-09-00851-g001){#F1}

Metabolic Diseases
------------------

In adipose tissue, the role of aquaglyceroporins in metabolic diseases, and more especially in obesity and metabolic syndrome, has extensively been reviewed ([@B42]; [@B98]; [@B77]; [@B95]; [@B74]; [@B32]). Therefore, only a brief overview will be presented on this topic.

Depending on their genetic background, *Aqp7* knockout mice were shown to either develop or not develop obesity ([@B51]; [@B55]; [@B104]). The site of AQP7 expression, exclusively in endothelial cells ([@B140]; [@B80]) or in endothelial cells and adipocytes ([@B75]; [@B112]), could account for the susceptibility of mice to develop obesity ([@B141]). In n3-polyunsaturated fatty acids (PUFA) depleted rats, an animal model of metabolic syndrome, a decrease in AQP7 protein levels was observed without any modification in *Aqp7* mRNA levels \[possibly due to the lack of PPARγ activation concomitant to PUFA depletion, as PPARγ normally activates the transcription of AQP7 ([@B70])\] and glycerol transport ([@B125]).

As human *AQP7* gene is localized in a chromosomal region with reported linkage to type 2 diabetes (T2D) ([@B92]; [@B84]) and the metabolic syndrome ([@B90]), AQP7 expression has been particularly studied in patients suffering from obesity, T2D and metabolic syndrome. *AQP7* gene missense and silent mutations were not correlated with obesity and T2D ([@B71]). In adipose tissue, deregulation of AQP7 expression has been documented in obese subjects, with studies presenting opposing results reporting either a decrease or increase in AQP7 expression ([@B100]; [@B26]; [@B127]; [@B24]; [@B110]; [@B130]; [@B35]). These apparent contradictory data might be related to the clinical characteristics of the obese phenotype of the obese subjects, as well as their gender ([@B132]). Very recently studies have shown that insulin resistance of adipose tissue could be related to lower KLF-15 expression that could reduce *AQP7* expression ([@B72]). On the other hand, lipopolysaccharide, known to play an important role in obesity ([@B14]), decreased glycerol permeability and increased TAG content in 3T3-L1 adipocytes, without modification of AQP7 protein expression ([@B31]). Species-related expression and proposed physiological and pathophysiological roles of adipose tissue aquaglyceroporins are summarized in **Table [1](#T1){ref-type="table"}**.

###### 

Reported species-related expression and suggested physiological and pathophysiological relevance of adipose tissue aquaglyceroporins.

  Aqua-glyceroporin   Cell type                  Suggested physiological role                           Suggested pathophysiological involvement
  ------------------- -------------------------- ------------------------------------------------------ -------------------------------------------------
  AQP3                Adipocytes (h, m, r)       TAG synthesis; uptake of glycerol (low contribution)   
                                                 Lipolysis; release of glycerol                         
  AQP7                Adipocytes (h, m, r)       TAG synthesis; uptake of glycerol (low contribution)   Obesity; Insulin resistance; metabolic syndrome
                                                 Lipolysis; release of glycerol                         
                      Endothelial cells (h, m)   Unknown                                                
  AQP9                Adipocytes (h, m)          TAG synthesis; uptake of glycerol (low contribution)   
                                                 Lipolysis; release of glycerol                         
  AQP10               Adipocytes (h)             Unknown                                                

h, human; m, mouse; r, rat.

Role of Aquaglyceroporins in Liver
==================================

Physiological Conditions
------------------------

### Roles of Aquaglyceroporins in Liver Glycerol Metabolism and Metabolic Homeostasis

Glycerol is an intermediate metabolite of physiological relevance in energy metabolism. Indeed, glycerol is a direct source of glycerol-3-phosphate (G3P), an important substrate for hepatic gluconeogenesis during fasting and for TAG synthesis ([@B15]; [@B128]). Glycerol can derive from G3P ([@B115]), produced by glucose use through glycolysis, or the conversion of pyruvate, lactate and alanine through gluconeogenesis. Liver plays a central role in glycerol metabolism, due to its major (70--90%) contribution to the whole-body glycerol metabolism ([@B128]). To different extents and with different cellular distributions, liver expresses all four aquaglyceroporins, with AQP9 being by far the most expressed.

In rodents and human, AQP9 is expressed at the sinusoidal domain of the hepatocyte plasma membrane, facing the space of Disse ([@B40]; [@B22]; [@B85]). In human, AQP9 expression is higher in hepatocytes, as compared to the other few tissues in which it is found ([@B85]). In both rodents and human, AQP9 represents the major pathway for glycerol import from portal blood to hepatocytes ([@B68]; [@B19]). The membrane permeation represents the rate limiting step in glycerol use by the liver ([@B82]). Once into the hepatocyte, glycerol is promptly converted into G3P by GK. In short term fasting, G3P is particularly important as a substrate for *de novo* synthesis of glucose (gluconeogenesis) ([@B15]; [@B68]; [@B19]; [@B17]; [@B10]). In rodents, liver *Aqp9* is transcriptionally downregulated by insulin ([@B73]), explaining why streptozotocin-induced type 1 diabetes in rodents ([@B22]) and insulin resistance in human ([@B134]) are associated with an increase in the hepatic levels of AQP9. Consistently, ablation of *Aqp9* in obese diabetic leptin receptor-deficient *db*/*db* mice decreases plasma glucose levels by 10--40% ([@B136]). A model for the hepatic glucose metabolism based on Hill and step functions was recently devised as a way to integrate the hepatic entry and handling of glycerol in the glucose-insulin axis taking into account the (i) refilling/depletion of glycogen stores during the feeding or fasted state, (ii) the influence of plasma glycerol and (iii) the liver glycerol permeability to hepatic AQP9 protein levels ([@B33]). To follow, a system of first-order ordinary differential equations was devised delineating the dynamical involvement of AQP9 in mouse liver glycerol permeability ([@B44]). Thus, assuming the liver glycerol permeability depends on the levels of AQP9 in hepatocyte, a mathematical function was generated describing the time course with which AQP9 is involved in mouse hepatic glycerol metabolism under different nutritional conditions. The theoretical relationship was derived fitting experimental data obtained with mice in the fed, starved or re-fed states. Such a model, appropriately adapted to the human liver, has good potentials to be used as a whole body-model for glucose metabolism in normal and metabolic disorders.

Liver AQP9 has also considerable relevance to lipid metabolism as G3P also represents a key substrate for TAG synthesis ([@B130]; [@B77]). Coordinately, AQP9-depleted (*Aqp9*^−/−^) mice display reduced liver glycerol permeability and higher levels of plasma glycerol and TAG compared to wild type (WT) (*Aqp9*^+/+^) mice ([@B136]; [@B19]). Liver AQP9 is also controlled transcriptionally by leptin ([@B130], [@B133]), however, surprisingly, the regulations exerted by both insulin and leptin on AQP9 appear to be distinct when comparing rodents with humans ([@B77]; [@B17]). In HepG2 cells, a human hepatocellular carcinoma cell line, insulin increased while leptin decreased AQP9 expression through the activation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling cascade ([@B130]) and AMP protein kinase (AMPK), via forkhead box a2 (Fox a2) ([@B164]). However, the regulation exerted by both insulin and leptin on human AQP9 expression remains an open question considering that a recent work did not detect AQP9 expression in HepG2 cells ([@B85]). Additional work is therefore needed to fully assess the way by which insulin and leptin modulate AQP9 expression in human liver.

In rat, the fasting-induced increase of liver AQP9 expression resulted a 2.6 times higher level in males than females ([@B79]). Consistently, during fasting, male rats displayed unmodified plasma glycerol levels, whereas female rats displayed increased plasma glycerol levels. This was paralleled by the higher liver glycerol permeability in males than in females. Ovariectomy led to a fasted-induced profile comparable to that observed in male rats with increased liver AQP9 expression and unmodified plasma glycerol levels. These observations, together with the data acquired with the studies using cultured hepatocytes exposed to 17β-estradiol and an estrogen receptor β-agonist, suggest that the gender specific regulation of AQP9 during fasting contributes to the higher levels of plasma glycerol found in female rats than in male rats ([@B79]). Decreased AQP9 protein levels were found in periportal hepatocytes of male rats in response to the peroxisome proliferator-activated receptor α (PPARα) ([@B78]). Obese women showed lower liver glycerol permeability compared to obese men whereas the hepatic levels of AQP9 between the two genders were comparable ([@B134]). This significant observation may help explain why insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD) have lower incidence in women than men. Gender-specific differences have been found as well for AQP3 and AQP7, two other aquaglyceroporins, with metabolic relevance in the adipose tissue (for review see [@B132]).

Probably due to the broad selectively of its channel, hepatocyte AQP9 seems to be of pleiotropic relevance, as roles in bile formation ([@B18]; [@B122]) and hepatic extrusion of catabolic urea ([@B67]) have been reported. AQP9 has also been described to allow excretion of arsenic from the liver ([@B23]). AQP9 immunoreactivity has been also detected in the cholangiocytes lining the intrahepatic bile ducts ([@B49]), however, the related physiological significance remains undefined.

In addition to AQP9, but to a lesser extent and undermined by conflicting results, human hepatocytes have been also reported to express the other three aquaglyceroporins, AQP3, AQP7, and AQP10 ([@B134]; [@B49]). Women showed increased hepatic transcript levels of *AQP3* compared to men, but no gender dimorphism in the liver gene expression of *AQP7* and *AQP10* was observed ([@B134]). Leptin upregulated AQP3 and downregulated AQP7 in the HepG2 hepatocytes ([@B130]). However, in spite of these observations, the physiological meaning of hepatocyte AQP3, AQP7, and AQP10 in humans, if any, remains elusive. Human hepatic stellate cells (HSC) express AQP3 whose levels were reported to decrease during cell activation ([@B147],[@B148]). AQP3 is also found in human Kupffer cells ([@B49]) where it may play a role in cell repopulation during liver regeneration and be involved in the migration and proinflammatory secretion of cytokines that these cells undergo in the course of liver pathologies. Overall, the cellular and subcellular localization of AQP3, AQP7, and AQP10 in liver does not seem to overlap with that of AQP9, and additional studies are warranted to fully clarify their roles in liver. AQP9 ([@B150]), in addition to AQP1 ([@B101]), and AQP8 ([@B150]; [@B101]), has been located in rat hepatocyte membrane microdomains enriched in high-cholesterol, sphingomyelin and caveolin-1. Upon glucagon stimulation, the presence of AQP8, but not of AQP9, was increased in these membrane microdomains ([@B150]).

The reported localization and suggested physiological relevance of liver aquaglyceroporins are described in **Table [2](#T2){ref-type="table"}**. **Figure [1](#F1){ref-type="fig"}** summarizes the roles played by AQP9 in liver under fasted and fed states in mouse.

###### 

Reported localization and proposed physiological and pathophysiological relevance of liver aquaglyceroporins.

  Aquaglyceroporins   Cell type               Subcellular location   Suggested physiological role                                                                                                                                                 Suggested pathophysiological involvement
  ------------------- ----------------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  AQP3                Kupffer cells (h)       Undefined              Repopulation of Kupffer cells in liver regeneration                                                                                                                          Kupffer cell migration and proinflammatory cytokine secretion
                      Hepatocytes (h)         Undefined              Uptake of glycerol?                                                                                                                                                          Insulin resistance?
                      Stellate cells (h)      Undefined              Cell activation                                                                                                                                                              Hepatic steatosis (I148M variant)
  AQP7                Hepatocytes (h, m)      Cyt; others?           TAG synthesis; uptake of glycerol?                                                                                                                                           Insulin resistance
                      Cholangiocytes (h)      APM                    Unknown                                                                                                                                                                      
                      Endothelial cells (h)   APM                    Unknown                                                                                                                                                                      
  AQP9                Hepatocytes (h, m, r)   BLPM                   Uptake of portal glycerol (gluconeogenesis; TAG synthesis); import of water from portal blood (bile formation); urea extrusion; arsenic detoxification; liver regeneration   NAFLD; NASH; obesity; T2D; hepatocellular carcinoma
                      Cholangiocytes (h)      Undefined              Unknown                                                                                                                                                                      
  AQP10               Hepatocytes (h)         Undefined              Exit of glycerol during lipolysis                                                                                                                                            

APM, apical plasma membrane; BLPM, basolateral plasma membrane; h, human; m, mouse; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; r, rat; TAG, triacylglycerols; T2D, type 2 diabetes mellitus.

Liver Aquaglyceroporins in Disease
----------------------------------

Consistent with their role in facilitating glycerol transport into and out of cells and the related control of fat accumulation and glucose homeostasis, hepatic aquaglyceroporins, in particular AQP9, are reported to be implicated in metabolic disorders affecting the liver (**Table [2](#T2){ref-type="table"}**). The roles in metabolic diseases played by the hepatic AQPs belonging to the classic and unorthodox groups of AQPs have been reviewed elsewhere ([@B123]).

### Liver Aquaglyceroporins in Fatty Liver Disease, Obesity, Diabetes Mellitus and Hepatocellular Carcinoma

The pathology of NAFLD is multifactorial and characterized by ectopic accumulation of TAG in the liver ranging from simple fatty liver (hepatic steatosis) to NASH and to cirrhosis (irreversible, advanced scarring of the liver) ([@B27]). NAFLD is often associated with the metabolic syndrome often characterized by obesity and diabetes mellitus with insulin resistance. NAFLD and NASH are the object of intensive investigation, especially regarding the pathogenic pathways leading to excessive TAG accumulation within the liver parenchyma ([@B151]). AQP9 is hypothesized to be involved in the hepatic synthesis of TAG in NAFLD as indicated by (i) the amelioration of high fat diet-induced NAFLD in rats with knockdown of hepatic AQP9 ([@B16]), (ii) the increase in hepatocyte AQP9 expression accompanying the development of fatty liver in diet-induced obese (DIO) mice ([@B56]), (iii) the impairment of hepatocyte AQP9 and glycerol permeability found in an animal model of NAFLD \[leptin-deficient mice (*ob*/*ob* mice)\] ([@B45]) and in patients with obesity, insulin-resistance and NAFLD ([@B134]). However, some data do not support this hypothesis as *db/db* mice made AQP9 knockdown had similar TAG content as *db/db* mice ([@B143]), and as unmodified AQP9 expression was found in obese *ob/ob* mice ([@B133]). The downregulation of AQP9 during obesity and/or diabetes could represent a compensatory mechanism selected at decreasing substrate availability for *de novo* TAG synthesis, thereby counteracting the ectopic accumulation of TAG into hepatocytes, and reducing gluconeogenesis, thereby thwarting the progression of hyperglycemia ([@B45]; [@B134], [@B132]). However, in patients with morbid obesity, no relationship could be found between AQP9 expression and the degree of hepatic steatosis or fibrosis ([@B110]). N3-PUFA (ω3 polyunsaturated fatty acids)-depleted female rats (an animal model of metabolic syndrome displaying various features of the disease including the hepatic over-accumulation of TAG) showed reduced AQP9 protein levels and increased hepatic glycerol uptake as compared to control animals ([@B124]). It is therefore conceivable that AQP9 increases early during onset of steatosis while decreases at a later stage of the disease, when fat accumulation becomes excessive. Thus, the involvement of AQP9 in fatty liver should be contextualized within the origin of the disease, pathogenic profile and sex of the investigated animals and subjects. Further studies are therefore required to fully assess the etiopathological involvement and modulation of AQP9 in NAFLD-NASH. Nevertheless, the pharmacological interest toward liver AQP9 is strong as this aquaglyceroporin has good potentials to be a novel molecular target for therapeutic intervention in NAFLD and NASH. While selective small molecule AQP9 inhibitors with low micromolar IC50 values have already been reported and work is ongoing to increase the aqueous solubility of such blockers ([@B68]; [@B158]), preliminary studies using NAFLD cell models showed that silencing of AQP9 prevents or alleviates the degree of steatosis ([@B159]).

AQP9 seems to be of minor pathophysiological relevance in the fatty liver disease of alcoholic origin. A rapid increase in glycerol import and cell size was seen when rat primary hepatocytes were acutely exposed to acetaldehyde, an oxidation product derived from ethanol by the action of the hepatic enzyme alcohol dehydrogenase ([@B126]). The acute effects of acetaldehyde, while mediated by AQP9, were interpreted as mostly due to the binding of acetaldehyde to hepatocyte membranes and consequent changes in cell permeability. Exposure to ethanol, in spite of not changing AQP9 expression, increased the activity of GK and PEPCK (phosphoenolpyruvate carboxykinase), leading to increased production of G3P, which thereby could contribute to alcoholic hepatic steatosis ([@B126]).

Contrary to liver steatosis, a recent work using subcutaneously xenografted liver tumors in nude mice showed that hepatic AQP9 overexpression inhibit hepatocellular carcinoma by upregulating forkhead-box protein O1 (FOXO1) expression ([@B83]). Decreased AQP9 expression was shown in hepatocellular carcinoma ([@B165]). Novel strategies based on clinically feasible approaches may be developed to restore AQP9 expression for the prevention and treatment of hepatocellular carcinoma.

A recent study showed that treatment with estrogen protects against ovariectomy-induced hepatic steatosis by increasing hepatocyte AQP7 expression ([@B43]). Liver AQP7 was therefore suggested to play an important role in lipogenesis representing a potential target for the prevention and treatment of fatty liver disease in postmenopausal women.

Human HSC AQP3 was suggested to interact with the PNPLA3 I148M variant in causing hepatic steatosis, NASH, fibrosis and cancer ([@B147]). A profound reduction of AQP3 in HSC carrying the PNPLA3 I148M polymorphism correlated with decreased PPARγ activation, which could be rescued by rosiglitazone, a PPARγ agonist, and blocking of JNK. This finding triggers the appealing idea that targeting AQP3 within HSCs activation may lead to the development of new treatments for liver fibrosis in PNPLA3 I148M patients.

Role of Aquaglyceroporins in Endocrine Pancreas
===============================================

Physiological Conditions
------------------------

Endocrine pancreas accounts for 10% of total pancreas and is made of islets of Langerhans dispersed within the pancreatic tissue. Islets of Langerhans are constituted of five types of cells: (1) β-cells producing insulin; (2) α-cells producing glucagon; (3) δ-cells producing somatostatin; (4) γ-cells producing pancreatic polypeptide; and (5) 𝜖-cells producing ghrelin ([@B76]; [@B5]; [@B66]). Endocrine pancreas participates to the control of fuel metabolism by secreting insulin in post-prandial state, and glucagon in pre-prandial state.

To the best of our knowledge, the expression of aquaglyceroporins in human endocrine pancreas has not yet been documented. However, AQP7 is expressed in rat and mouse β-cells ([@B104]; [@B11]; [@B91]). While *Aqp3* and *Aqp9* mRNA were undetectable in mouse β-cells ([@B104]), this was also the case in rats with the exception of *Aqp9* mRNA that was detectable in 10% of the studied samples ([@B106]). Additional studies are necessary to clearly assess the presence of other aquaglyceroporins besides AQP7 in β-cells.

In β-cells, AQP7 has been shown to play a role in intracellular glycerol content and both insulin production and secretion (**Table [3](#T3){ref-type="table"}**). As compared to WT mice, *Aqp7* knockout mice display a reduction in β-cells number, size and insulin content ([@B104]). In addition the *Aqp7* knockout mice presented increased intraislet concentration of glycerol and TAG, as well as increased GK activity, but abolished forskolin-induced glycerol release ([@B104]).

###### 

Reported species-related expression and suggested physiological and pathophysiological relevance of pancreas aquaglyceroporins.

  Aqua-glyceroporin   Cell type                  Suggested physiological role           Suggested pathophysiological involvement
  ------------------- -------------------------- -------------------------------------- ------------------------------------------
  AQP3                Absent in β-cells (m, r)                                          
  AQP7                β-cells (m, r)             Insulin secretion                      Obesity
                                                 TAG synthesis; uptake of glycerol      
                                                 Lipolysis; release of glycerol         
                                                 Regulation of β-cell size and number   
  AQP9                β-cells (r)^∗^                                                    
  AQP10               Undefined                                                         

m, mouse; r, rat;

∗

present in ± 10% of samples.

Glycaemia was measured in several *Aqp7* knockout mice models. However, depending on their genetic background, these *Aqp7* deficient mice presented different phenotypes characterized by either normal glycaemia with underdetermined insulinemia ([@B140]), normal glycaemia with hyperinsulinemia ([@B104]), or hyperglycaemia and hyperinsulinemia ([@B55]). One can hypothesize that the resulting phenotype of *Aqp7* knockout mice results from combined interactions between *Aqp7* and various other gene products; unraveling the *Aqp7* interactome, therefore will be necessary for a better understanding.

In the current model of insulin secretion, the sequential mechanisms accounting for insulin secretion involve: glucose uptake ensured by the glucose transporter type 2 (GLUT2), metabolism of glucose, increase in intracellular ATP concentration, inhibition of ATP-sensitive potassium channels, membrane depolarization, opening of voltage-dependent calcium channels, increase in intracellular calcium concentration, and finally insulin vesicle degranulation ([@B53]) (**Figure [2](#F2){ref-type="fig"}**). During the glucose-induced insulin secretion, glucose also induces β-cell swelling that may affect cell activity ([@B108]). Indeed, in response to extracellular hypotonicity, β-cells swelling induces the activation of volume-regulated anion channels (VRAC), leading to subsequent cell depolarization, activation of voltage-dependent calcium channel, increase in intracellular calcium concentration, and finally insulin release ([@B12]; [@B39]). When β-cells or BRIN-DB 11 cells are exposed to extracellular isosmotic addition of glycerol, cells undergo cell swelling, VRAC activation, plasma membrane depolarization, electrical activity and insulin release ([@B11]; [@B36]; [@B157]). This activation of β-cell is likely due to both glycerol entry and metabolism ([@B11]). Exposure of β-cells from *Aqp7* knockout mice, to either extracellular isosmotic addition of glycerol, extracellular hypotonicity or increased [D]{.smallcaps}-glucose concentration causes decreased insulin release as compared β-cells from WT mice ([@B91]). The involvement of glycerol and AQP7 in the regulation of insulin secretion is in agreement with previous studies showing that glucose-stimulated insulin secretion correlates with β-cell lipolysis ([@B163]; [@B118]; [@B162]). Therefore, it is hypothesized that AQP7 plays a dual role in the regulation of insulin secretion by participating to glycerol flow (entry and exit), and by directly or indirectly acting at a distal downstream site in the insulin secretion pathway ([@B91]) (**Table [3](#T3){ref-type="table"}**).

![Role of AQP7 in β-cell insulin secretion. Following glycerol entry via AQP7 in β-cell (1), β-cell undergo cell swelling (2) leading to the activation of volume-regulated anion channel (VRAC) with concomitant Cl^-^ exit (3) and subsequent cell membrane depolarization (4). Cell membrane depolarization then activates voltage-sensitive calcium channels leading to intracellular calcium increase (5) provoking insulin exocytosis (6).](fphys-09-00851-g002){#F2}

Based on the results from the literature, following an increase in circulating glycerol levels (in response to the induction of lipolysis in adipocytes), it is hypothesized that local β-cells intracellular glycerol concentration rises and induces activation of β-cells. In addition, β-cells activation, subsequent to intracellular glycerol concentration increase, may occur following a rise in insulin downregulating AQP7 expression ([@B70]; [@B71]), or a modification of the *Aqp7* gene affecting the expression or the activity of AQP7. Insulin resistance characterized by increase in blood glucose (due to decreased glucose uptake by tissues) and increase in insulin levels may then also prompt an increase in β-cells intracellular glycerol concentration ([@B157]).

Metabolic Diseases
------------------

Very little data are available in the literature concerning the expression and function of aquaglyceroporins in the endocrine pancreas in relation to metabolic diseases. One recent study, however, has shown that obese rats pancreas had increased *Aqp7* mRNA and protein levels, as compared to lean rats, with *Aqp7* transcripts being negatively correlated with total ghrelin levels and glucagon-like peptide 1 (GLP-1) (lower in obese rats) ([@B106]). In addition, sleeve gastrectomy in obese rats restored the altered AQP7 expression in endocrine pancreas and improved pancreatic β-cell function ([@B106]). Further studies will be required to determine if AQP7 could become a useful drug-target in β-cells for the treatment of metabolic diseases.

Aquaglyceroporins as Drug Targets for Metabolic Diseases
========================================================

A variety of drugs have been identified as capable of modulating either the expression and/or the activity of aquaglyceroporins. The effects as well as the potential therapeutic use of aquaglyceroporin modulators are described with main focus on their relationship to metabolic diseases. More in general, most AQPs trigger strong interest for their pharmacological potentials in medical treatment of pathologies of high epidemiological impact such as the oxidative stress-related diseases ([@B146]).

Gold-Based Compounds and Nucleoside Analogs
-------------------------------------------

Some gold(III)-base compounds have been shown to act as modulators of aquaglyceroporins. The gold(III) compound complex \[Au(phen)Cl~2~\]Cl (phen = 1,10-phenanthroline; Auphen) has been shown to be a very selective and potent blocker of AQP3 by binding to its selectivity filter domain, and to the side chain of Cys40 located close to the constriction pore ([@B103]; [@B139]; [@B34]). Similarly, Hg^2+^, a non-selective AQPs inhibitor, has been shown to inhibit AQP3 glycerol permeability by interacting with Cys40, while inhibiting water flux due to the displacement of Arg128 concomitant to rupture of the hydrogen bond with Phe147 ([@B144]). The Auphen complex was also shown to inhibit both mouse and human AQP7 ([@B93]). By homology modeling, molecular docking studies, and non-covalent docking studies, Auphen was shown to block AQP7 by direct binding to Met47, located in the pore entrance facing the cytoplasm ([@B93]). From a cellular point of view, Auphen was shown to inhibit cell proliferation of several cell types, including 3T3-L1 cells ([@B139]).

Other gold compounds, including \[Au(bipy)Cl~2~\]^+^ (bipy = 2,2′-bipyridine; Aubipy), have been shown to also inhibit AQP3 (for review see [@B103], [@B102]; [@B9]; [@B34]; [@B48]; [@B142]).

AQPs have been shown to contribute to cell migration, metastasis and angiogenesis ([@B156]). In this context, via its glycerol-mediated transport, AQP3 is involved in epidermal cell proliferation where *Aqp3* knockout mice displayed both impaired epidermal cell proliferation and resistance to skin tumorigenesis ([@B52]). Interestingly, high AQP3 expression has been associated with other types of cancers (for review, see [@B99]), including for example colorectal carcinoma ([@B113]), pancreatic ductal carcinoma ([@B37]; [@B59]), hepatocellular carcinoma ([@B29]), lung cancer ([@B86]), and gastric adenocarcinoma ([@B60]; [@B28]). In addition, AQP3 plays a role in cancer cell invasion and in aggravation of epithelial-to-mesenchymal transition (for review, see [@B99]). In addition, some nucleoside analogs used in chemotherapy of solid tumors, 5′-deoxy-5-fluorouridine (5′-DFUR) and 2′-deoxy-2′,2′-difluorocytidine (gemcitabine), stimulate AQP3 expression and cell cycle arrest ([@B152]). Glycerol transport, but also hydrogen peroxide transport, could mediate the downstream effect of increased AQP3 expression leading to cell cycle arrest and cytotoxicity ([@B109]).

The potential beneficial use of AQP3 inhibitors or modulators (decreasing AQP3 expression) remains to be evaluated for cancer treatment. In addition, radiolabeled glycerol could be used as a molecular probe targeting aquaglyceroporins to estimate their expression in different tissues *in vivo*, including tumors ([@B137]).

In adipose tissue, aquaglyceroporins, and in particular AQP7, represent potential drug target for the treatment of obesity and metabolic syndrome ([@B42]; [@B96]; [@B155]). As AQP3 expression is increased in mouse 3T3-L1 differentiated into adipocytes ([@B30], [@B31]), and in epididymal and subcutaneous adipocytes from high-fat diet rats developing obesity ([@B106]), and thereby could be involved in adipose tissue hyperplasia during obesity, AQP3 might also become an additional interesting drug target for the treatment of obesity.

Metalloids
----------

Metalloids, that are physiologically harmful to humans, are still being used in the form of arsenic or antimony containing drugs to treat certain diseases and forms of cancers ([@B117]). *Xenopus laevis* oocytes injected with aquaglyceroporins cRNA revealed that human AQP3, AQP7, and AQP9 conducted the movement of AsIII across cell, while AQP10 did not ([@B88]). However, in contrast to these observations, human *Aqp10* knockdown in human colorectal cell line Caco-2 resulted in reduced As^III^ accumulation, suggesting that AQP10 might facilitate As^III^ transcellular flow ([@B21]) as well. Whether human AQP10 is permeable to As^III^ awaits additional studies. Mouse and rat AQP7 and AQP9 were also shown to be permeable to As^III^ ([@B88]; [@B23]). Monomethylarsonous acid (MMA^III^), one of the major methylation products of inorganic arsenic, can permeate through rat AQP9, human AQP9 and mouse AQP7, but not human AQP7 ([@B89]; [@B87]; [@B105]). In addition, human AQP9 is permeable to two other major methylation products of inorganic arsenic: monomethylarsonic acid (MMA^V^) and dimethylarsenic acid (DMA^V^) ([@B105]). Human AQP9 was also found to be permeable to lactate, ionic selenite and monomethylselenic acid (MSeA) ([@B46]). MSeA could be used for the prevention and treatment of several cancer types, such as pancreatic cancer ([@B160]) and lung cancer ([@B145]), as it induces cell cytotoxicity. Lower AQP9 expression has been related with non-response to adjuvant chemotherapy, comprising amongst others a nucleoside analog, in colorectal cancer ([@B38]). In addition, AQP9 was recently shown to enhance the cytotoxic effect of nucleoside analogs in colorectal cancer, and could thereby be used as a novel predictor for the benefit of nucleoside analog chemotherapy in the disease ([@B58]). In hepatocellular carcinoma decreased AQP9 expression has been associated with apoptosis resistance, invasion and epithelial-to-mesenchymal transition ([@B64]; [@B119]; [@B83]; [@B29]). Downregulation of aquaglyceroporin expression may lead to a metalloid resistant and/or adjuvant resistant phenotype. However, drugs aiming at specifically increasing AQP9 expression in tumor cells will sensitize them to metalloid compounds and favor the anticipated cytotoxic effects ([@B116]). These data emphases the efficacy of using combined therapeutic approaches acting in synergy for the treatment of cancers. Consequently, chemotherapy would benefit from the identification of novel drugs that could specifically increase aquaglyceroporin expression in cancer cells.

Due to its permeability to glucogenic glycerol ([@B68]; [@B19]; [@B46]), AQP9 represents an interesting drug target in the pharmacological modulation of gluconeogenesis.

Antidiabetic Drugs
------------------

Troglitazone (a thiazolidinedione activating PPARγ) and tolbutamide (a sulfonylurea blocking potassium channels) were shown to significantly decrease AQP3 expression in Caco-2 cells, while metformin \[belonging to the beguanide family and activating AMP-activated protein kinase (AMPK)\] and tolbutamide did not alter AQP3 expression ([@B8]). PPARγ agonists have also been shown to increase adipose tissue AQP7 expression ([@B70]; [@B71]; [@B81]). It remains to be determined if rosiglitazone (another thiazolidinedione activating PPARγ) and metformin, that restored insulin secretion in pancreatic β-cells chronically exposed to free fatty acids or high glucose ([@B120]; [@B129]), increased AQP7 expression. Further studies are necessary to study the effects of antidiabetic drugs on aquaglyceroporin expression, pertaining to key tissues involved in the control of energy metabolism, including adipose tissue, liver and endocrine pancreas. As a result, this would allow a better understanding of the mechanisms accountable for the beneficial effects of antidiabetic drugs in metabolic diseases, and develop new therapeutic strategies. Therapeutic synergy between metformin, suppressing hepatic gluconeogenesis ([@B121]) and restoring insulin secretion ([@B120]; [@B129]), and drugs, specifically decreasing aquaglyceroporin hepatic expression or activity, could be beneficial for the treatment of T2D characterized by increased hepatic gluconeogenesis and hepatic lipid accumulation leading to hepatic insulin resistance ([@B121]).

Other Compounds
---------------

Phloretin, a natural antioxidant phenol acting as a potent inhibitor of glycerol fluxes ([@B1]), inhibits urea and glycerol permeability in rat and human hepatocyte cell membranes ([@B19]; [@B67]; [@B134]). Recently, it has been shown that intraperitoneal administration of 10 mg/kg of phloretin (twice weekly) in mice fed a high-fat diet during 12 weeks reverted obesity, prevents weight gain, hyperinsulinemia, glucose intolerance, insulin resistance, and fatty liver ([@B4]). Moreover, intraperitoneal administration of 10 mg/kg of phloretin (twice weekly) in mice made obese by submitting them for 6 weeks to a high-fat diet improved insulin levels, insulin resistance and hepatic liver accumulation, but did not modify body weight or fasting blood glucose levels ([@B4]). These data suggest that phloretin could represent an additional pharmacological tool for the treatment of obesity and its associated metabolic diseases.

Obese *Aqp9* knockout mice are characterized by reduced fasting blood glucose levels as compared to obese WT *Aqp9* mice ([@B136]). Several AQP9 small molecule inhibitors were identified by screening a commercial compound library using a cell-based permeability assay ([@B68]; for review see [@B9]). The compounds showing the highest efficiency in blocking AQP9 were subjected to *in silico* molecular docking to a human AQP9 model and the compounds showing good docking properties were functionally tested using Chinese Hamster Ovary (CHO) cells expressing AQP9 ([@B68]). The putative binding sites of the most interesting compounds were then evaluated by site-directed mutagenesis and a cell water permeability assay of mutated AQP9 channels ([@B158]). Few additional patent compounds have been claimed to modulate AQP9 expression or activity, thereby being of therapeutic interest for the treatment of diseases (for review see [@B142]). In humans, AQP9 is expressed almost exclusively in the liver parenchyma with evident pharmacological advantages as a drug-target pathway. Given the relevance of AQP9 in facilitating the entry of glycerol, the carbon backbone of TAG, into hepatocytes, it is reasonable to think that small chemical compounds with micromolar-submicromolar potency in blocking selectively the AQP9 channel, may be effective in counteracting the aberrant hepatic fat accumulation underlying NAFDL/NASH, pathologies for which several potential therapeutic approaches have been proposed while no established therapy does exist (for a review see [@B20]). As for T2D, structural analogs of HTS13286 featuring pharmacological and clinical sustainability offer worthy potential as new options in preventing end-stage liver disease, from simple steatosis to NAFLD/NASH and consequent liver fibrosis and hepatocarcinoma. Phytochemical modulation of AQP9 expression by nutraceutics counteracting excess hepatic lipid accumulation ([@B25]; [@B149]) is also worthy of investigation in preventing or improving prognosis of NAFLD/NASH. The heterocyclic compound HTS13286 is a selective and potent blocker of AQP9 with an IC~50~ of 1.5 μM ([@B68]), however, its scarce water solubility hampers its use *in vivo*. Design and synthesis of structural analogs of HTS13286 with improved hydrophilicity, pharmacodynamic and pharmacokinetic properties is therefore a worthwhile task.

Conclusion and Future Perspectives
==================================

A body of evidence indicates involvement of Adipose liver and endocrine pancreas aquaglyceroporins in the metabolic and energy control function exerted by these tissues. Metabolic relevance is also testified by the alterations in expression levels and regulation to which they undergo in clinical disorders associated with metabolic and energy dysfunction. While a number of reports have described aquaglyceroporins modulation by phytochemical compounds preventing or improving chronic metabolic diseases, investigation of their pharmacological potential is just picking up speed. New and more sustainable aquaglyceroporin inhibitors have been identified while others are subject to ongoing research. Development of therapeutic strategies targeting aquaglyceroporins may therefore offer promise for the management of a large spectrum of clinical disorders including metabolic and energy balance diseases. Overall, the study of biologically active phytochemicals and synthetic compounds as modulators of aquaglyceroporin expression or function is an emerging topic in which new and important achievements are anticipated.
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